VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
Status:
COMPLETED
Trial end date:
2024-06-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future.